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Abstract: The application of chondrogenic gene sequences to human bone marrow-derived
mesenchymal stromal cells (hMSCs) is an attractive strategy to activate the reparative activities of
these cells as a means to enhance the processes of cartilage repair using indirect cell transplantation
procedures that may improve the repopulation of cartilage lesions. In the present study, we examined
the feasibility of co-delivering the highly competent transforming growth factor beta (TGF-β) with
the insulin-like growth factor I (IGF-I) in hMSCs via recombinant adeno-associated virus (rAAV)
vector-mediated gene transfer prior to implantation in a human model of osteochondral defect (OCD)
ex vivo that provides a microenvironment similar to that of focal cartilage lesions. The successful
co-overexpression of rAAV TGF-β/IGF-I in implanted hMSCs promoted the durable remodeling of
tissue injury in human OCDs over a prolonged period of time (21 days) relative to individual gene
transfer and the control (reporter lacZ gene) treatment, with enhanced levels of cell proliferation
and matrix deposition (proteoglycans, type-II collagen) both in the lesions and at a distance, while
hypertrophic, osteogenic, and catabolic processes could be advantageously delayed. These findings
demonstrate the value of indirect, progenitor cell-based combined rAAV gene therapy to treat human
focal cartilage defects in a natural environment as a basis for future clinical applications.
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1. Introduction
Focal articular cartilage lesions remain a particularly challenging clinical problem in orthopaedics
due to the failure of the articular chondrocytes, the only cell population present in this highly specialized,
avascular tissue, to fully provide self-repair activities in sites of cartilage injury [1–4]. Equally critical,
none of the surgical options currently employed in orthopaedic surgery to mobilize or even supply
chondroregenerative progenitor cells, like those from the subchondral bone marrow (microfracture,
pridie drilling, stromal cell transplantation), can reliably support the strict reproduction of the original
hyaline cartilage in such lesions with a typical proteoglycan- and type-II collagen-based extracellular
matrix (ECM) [1–7]. Instead, a fibrocartilaginous repair tissue mostly composed of type-I collagen
is generated in sites of cartilage injury, without the proper mechanical integrity that would allow
to withstand mechanical loads over time, and that may progress towards irreversible, degenerative
osteoarthritis [1–4].
Strategies that aim to activate the chondroreparative properties of progenitor cells prior to
reimplantation in sites of cartilage damage may provide strong tools to overcome these hurdles,
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like approaches using gene therapy procedures that support the specific and long-term targeting of
cellular and biological pathways involved in cartilage repair [8,9]. In this regard, vectors derived
from the human adeno-associated virus (AAV) vector are particularly well suited to achieve these
goals from a translational perspective [10], as recombinant AAV (rAAV) constructs can safely and
durably transduce bone marrow-derived mesenchymal stromal cells (MSCs) at very high efficiencies
(about 100% for several weeks) [11–17]. While the rAAV-mediated transduction of MSCs from human
patients (hMSCs) has been attempted in a number of trials in vitro by delivering chondrotherapeutic
genes coding for the basic fibroblast growth factor (FGF-2) [13], transforming growth factor beta 1
(TGF-β1) [11,15], insulin-like growth factor I (IGF-I) [16], sex-determining region Y-type high-mobility
group box 9 transcription factor (SOX9) [14,17], little is known on the benefits of rAAV for the application
of genetically modified hMSCs in human focal cartilage defects in a native microenvironment.
In the present study, we focused on co-delivering TGF-β and IGF-I, two potent factors supporting
cartilage repair, in hMSCs via rAAV as improved cell regenerative platforms capable of enhancing
the repair activities in a human osteochondral defect (OCD) model system ex vivo, and, in light of
our previous work in vitro, showing the feasibility of co-applying these two candidates in settings
aiming at directly rejuvenating resident MSCs within a lesion [18]. For the first time, and to our
best knowledge, the current work demonstrates that the simultaneous overexpression of TGF-β and
IGF-I can be effectively achieved in rAAV-targeted hMSCs implanted within human OCDs, promoting
the sustained remodeling of the injured human articular cartilage (cell proliferation, hyaline ECM
deposition) over a prolonged period of 21 days while containing unwanted hypertrophic, osteogenic,
and catabolic processes relative to independent gene treatments and control condition (reporter lacZ
gene transfer). These findings show the value of using combined cell- and gene-based therapy via
rAAV as a significant means to enhance human cartilage repair in environmental conditions closely
resembling those in patients in vivo.
2. Experimental Section
2.1. Study Design
Human bone marrow-derived MSCs were prepared as high-density aggregates in defined
chondrogenic medium and subsequently transduced with the various rAAV vectors (total MOI = 8) as
candidate combined rAAV-hTGF-β/rAAV-hIGF-I (TGF-β/IGF-I; 40 µL each vector/aggregate) versus
independent rAAV-hTGF-β (TGF-β/lacZ) or rAAV-hIGF-I (IGF-I/lacZ) gene transfer (40 µL each
vector/aggregate) or absence of therapeutic gene (reporter rAAV-lacZ vector, i.e., lacZ condition; 80 µL
vector/aggregate). Aggregates were then implanted after 24 h in experimentally created human
osteochondral defects (OCDs; 1 aggregate/OCD) in a patient-match manner when both samples were
available that were maintained in defined chondrogenic medium for 21 days [5] to evaluate transgene
expression and to establish biochemical assays, immunohistochemical and histological analyses, and
real-time RT-PCR analyses (Figure 1).
2.2. Reagents
All reagents were purchased from Sigma, Munich (Germany) unless otherwise indicated.
The dimethylmethylene blue dye (DMMB) was from Serva, Heidelberg (Germany). The anti-TGF-β
(V) antibody was purchased at Santa Cruz Biotechnology (Heidelberg, Germany), the anti-IGF-I
(AF-291-NA) at R&D Systems (Wiesbaden, Germany), the anti-type-II collagen (II-II6B3) antibody at
NIH Hybridome Bank (university of Iowa, Ames, IA, USA), the anti-type-I collagen (AF-5610) antibody
at Acris Antibodies, Hiddenhausen (Germany), and the anti-type-X collagen (COL10) antibody at Sigma.
Biotinylated secondary antibodies and ABC reagent were from Vector Laboratories Alexis Deutschland,
Grünberg (Germany). The TGF-β and IGF-I Quantikine ELISAs were purchased at R&D Systems and
the AAVanced Concentration Reagent at System Bioscience (Heidelberg, Germany).
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Figure 1. Study design. Human bone marrow-derived mesenchymal stromal cells MSCs were 
prepared as high-density aggregates (2 × 105 cells/aggregate) in defined chondrogenic medium 
overnight, transduced with the various rAAV shuttles (TGF-β/IGF-I, TGF-β/lacZ, IGF-I/lacZ: 40 µL 
each vector/aggregate; lacZ: 80 µL vector/aggregate), and directly applied to human osteochondral 
defects (OCDs; 6-mm diameter) for further culture in defined chondrogenic medium for 21 days when 
the OCDs were processed to monitor transgene expression and for biochemical, 
immunohistochemical/histological, and real-time RT-PCR. 
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antibody was purchased at Santa Cruz Biotechnology (Heidelberg, Germany), the anti-IGF-I (AF-291-
NA) at R&D Systems (Wiesbaden, Germany), the anti-type-II collagen (II-II6B3) antibody at NIH 
Hybridome Bank (university of Iowa, Ames, IA, USA), the anti-type-I collagen (AF-5610) antibody at 
Acris Antibodies, Hiddenhausen (Germany), and the anti-type-X collagen (COL10) antibody at 
Sigma. Biotinylated secondary antibodies and ABC reagent were from Vector Laboratories Alexis 
Deutschland, Grünberg (Germany). The TGF-β and IGF-I Quantikine ELISAs were purchased at R&D 
Systems and the AAVanced Concentration Reagent at System Bioscience (Heidelberg, Germany). 
2.3. Cell and Osteochondral Defect Cultures 
Bone marrow aspirates were collected from the distal femurs of patients undergoing total knee 
arthroplasty (n = 3) with informed consent and according to the Helsinki Declaration. The study was 
approved by the Ethics Committee of the Saarland Physicians Council (No. 270-17). Firstly, bone 
marrow-derived hMSCs were isolated and expanded as previously described [13–19]. Briefly, freshly 
isolated hMSCs were washed, centrifuged in Dulbecco’s modified Eagle’s medium (DMEM) and the 
pellet obtained was resuspended in a mixture of red blood cell lysing buffer and DMEM in equal 
ratios. The mixture was washed, pelleted, and resuspended in DMEM containing 10% fetal bovine 
serum with 100 U/mL penicillin and 100 µL/mL streptomycin. Cells were plated in T75 flasks and 
kept incubated overnight at 37 °C under 5% CO2, and the medium was removed and replaced by 
growth medium with recombinant FGF-2 (1 ng/mL), with a medium change every 2–3 days. Cells 
were tested at passages 1–2 in order to avoid a shift in cell phenotype. 
Figure 1. Study design. Human bone marrow-derived mesenchymal stromal cells MSCs were prepared
as high-density aggregates (2 × 105 cells/aggregate) in defined chondrogenic medium overnight,
transduced with the various rAAV shuttles (TGF-β/IGF-I, TGF-β/lacZ, IGF-I/lacZ: 40 µL each
vector/aggregate; lacZ: 80 µL vector/aggregate), and directly applied to human osteochondral defects
(OCDs; 6-mm diamet r) for further culture in defined cho rogenic medium for 21 days when the OCDs
were processed to onitor transgene expr ssion and for biochemical, immunohistochemical/histological,
and real-time RT-PCR.
2.3. Cell and Osteochondral Defect Cultures
Bone marrow aspirates were collected from the distal femurs of patients undergoing total
knee arthroplasty (n = 3) with informed consent and according to the Helsinki Declaration.
The study was approved by the Ethics Committee of the Saarland Physicians Council (No. 270-17).
Firstly, bone marrow-derived hMSCs were isolated and expanded as previously described [13–19].
Briefly, freshly isolated hMSCs were washed, centrifuged in Dulbecco’s modified Eagle’s medium
(DMEM) and the pellet obtained as resuspended in a mixture of red blood cell lysing buffer and
DMEM in equal ratios. The mixture was washed, pelleted, and resuspended in DMEM containing
10% fetal bovine serum with 100 U/mL penicillin and 100 µL/mL streptomycin. Cells were plated
in T75 flasks and kept incubated overnight at 37 ◦C under 5% CO2, and the medium was removed
and replaced by growth medium with recombinant FGF-2 (1 ng/mL), with a medium change every
2–3 days. Cells were tested at passages 1–2 in order to avoid a shift in cell phenotype.
Human o t oarthritic (OA) cartilage biopsies excluding unaffected and fibrocartilage (n = 9; 6-mm
diameter; Mankin score = 7–9) randomly collected from the femoral condyle of patients undergoing
total knee arthroplasty were used to create standardized osteochondral defects (OCDs) with a 1-mm
biopsy punch [20,21] and briefly kept in growth medium for 2–3 days (to avoid a shift in cell phenotype
in the tissue) prior to direct implantation of the aggregates.
2.4. Plasmids and rAAV Vectors
All vectors were produced from the AAV-2-based vector plasmid pSSV9 [22,23]. It is known that
rAAV-lacZ carries the lacZ gene encoding the E. coli β-galactosidase (β-gal). Further, rAAV-hTGF-β
carries a human transforming growth factor beta 1 (hTGF-β) cDNA and rAAV-hIGF-I, a human
insulin-like growth factor I (hIGF-I) cDNA, both clones instead of lacZ in rAAV-lacZ, and all genes
were controlled by the cytomegalovirus immediate-early (CMV-IE) promoter/enhancer [13–17,21,24].
Subsequently, rAAV vectors were prepared as conventional (not self-complementary) vectors using a
helper-based system maintaining Adenovirus 5 and Ad8 in the 293 cell line (an adenovirus transformed
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human embryonic kidney packaging cell line) [13–17,21,24]. The vector preparations were purified
by dialysis using the AAVanced Concentration Reagent and titrated by real-time PCR as previously
described (approximately 1010 transgene copies/mL and ratio recombinant functional viral particles to
recombinant viral particles of about 1/500) [13–17,21,24].
2.5. rAAV-Mediated Gene Transfer
Bone marrow-derived hMSCs were prepared as high-density cultures (2 × 105 cells/aggregate) and
incubated in 150 µL chondrogenic medium (DMEM high glucose 4.5 g/L, ITS+ Premix, 1 mM pyruvate,
ascorbate 2-phosphate 37.5 ng/mL, 10−7 M dexamethasone, TGF-β3 10 ng/mL) overnight at 37 ◦C
under 5% CO2 prior to vector addition [13–17,21]. Aggregates were then directly transduced with the
vector treatments (TGF-β/IGF-I, TGF-β/lacZ, or IGF-I/lacZ: 40 µL each vector/aggregate; lacZ: 80 µL
vector/aggregate; total MOI = 8) and 150 µL chondrogenic medium was added for incubation at 37 ◦C
under 5% CO2 for 24 h. The (co-)transduced aggregates were then directly applied to the OCDs, with
incubation in 750 µL chondrogenic medium for 21 days. The chondrogenic medium was exchanged
every 2–3 days.
2.6. Transgene Expression
The expression of the candidate TGF-β and IGF-I gene products was assessed by specific ELISAs.
Briefly, the OCDs were washed twice with serum-free medium and kept in 750 µL DMEM for 24 h.
Culture supernatants were then collected and centrifuged and tested following the manufacturer’s
recommendations on a GENios spectrophotometer/fluorometer (Tecan, Crailsheim, Germany) [15–17,24].
2.7. Histological and Immonohistochemical Analyses
The OCDs were harvested after 21 days, fixed in formaldehyde (4%), washed with PBS, decalcified in
10% sodium citrate, 25% formic acid for two weeks at room temperature, and dehydrated in graded
alcohol [21]. Histological and immunohistochemical analyses were performed on paraffin-embedded
sections of OCDs (10µm). Sections were stained with hematoxylin and eosin (H&E) (cellularization) and
safranin O (matrix proteoglycans) [21]. The expression of type-II, -I, and -X collagen was monitored by
immunohistochemical detection using specific primary antibodies, biotinylated secondary antibodies,
and the ABC method with diaminobenzidine (DAB) as a chromogen [21]. Samples were analyzed
under light microscopy (Olympus BX 45, Hamburg, Germany).
2.8. Histomorphometric Analyses
The transduction efficiencies (% of TGF-β+ or IGF-I+ immunoreactive cells to the total cell
number), the cell densities (cells/mm2), and the intensities of safranin O staining and those of
type-II, -I, and -X collagen immunostaining (ratio tissue surface showing positive immunoreactivity for
particular collagen/total tissue surface) were measured using the SIS analysisSIS program (Olympus),
Adobe photoshop (Adobe Systems, Unterschleissheim, Germany), Scion Image (Scion Corporation,
Frederick, MD, USA) at three random sites standardized for their surface or using serial histological or
immunohistochemical sections [21]. Sections were also scored to evaluate the cartilage surrounding
the OCDs (magnification × 10) and the implanted aggregates (magnification × 20) for uniformity and
intensity using a modified Bern Score grading system [19,21]: 0 (no staining), 1 (heterogenous and/or
weak staining), 2 (homogeneous and/or moderate staining), 3 (homogeneous and/or intense staining),
4 (very intense staining).
2.9. Biochemical Analyses
The OCDs were collected after 21 days of culture and digested in papain to determine the DNA
contents by using the Hoechst 33,258 fluorometric assay, the proteoglycan contents by binding to
the dimethylmethylene blue dye (DMMB), and the total cellular protein contents for normalization
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with the Pierce protein assay (Pierce Thermo Scientific, Fisher Scientific, Schwerte, Germany) [21].
Measurements were performed with a GENios spectrophotometer/fluorometer (Tecan).
2.10. Real-Time RT-PCR Analyses
Total RNA was extracted from the OCDs containing the aggregates but excluding bone tissue
(RNeasy Protect Mini kit, Qiagen, Hilden, Germany) for reverse transcription (1st Strand cDNA
Synthesis kit, avian myeloblastis virus (AMV) (Roche Applied Science, Mannheim, Germany).
cDNA amplification was performed via SYBR Green real-time RT-PCR (Stratagene, Agilent Technologies,
Waldbronn, Germany) maintaining initial incubation (95 ◦C, 10 min), 55 cycles of amplification
(denaturation (95 ◦C, 30 s), annealing (55 ◦C, 1 min), extension (72 ◦C, 30 s), denaturation (95 ◦C
1 min), and final incubation (55 ◦C, 30 s). The primers employed were: SOX9 (chondrogenic marker)
(forward 5′-ACACACAGCTCACTCGACCTTG-3′; reverse 5′-GGGAATTCTGGTTGGTCCTCT-3′),
type-II collagen (COL2A1, chondrogenic marker) (forward 5′-GGACTTTTCTCCCCTCTCT-3;
reverse 5′-GACCCGAAGGTCTTACAGGA-3′), aggrecan (ACAN, chondrogenic marker) (forward
5′-GAGATGGAGGGTGAGGTC-3′; reverse 5′-ACGCTGCCTCGGGCTTC-3′), type-I collagen
(COL1A1, fibrocartilage and osteogenic marker) (forward 5′-ACGTCCTGGTGAAGTTGGTC-3′;
reverse 5′-ACCAGGGAAGCCTCTCTCTC-3′), type-X collagen (COL10A1, hypertrophic marker)
(forward 5′-CCCTCTTGTTAGTGCCAACC-3′; reverse 5′-AGATTCCAGTCCTTGGGTCA-3′),
matrix metalloproteinase 13 (MMP13, marker of terminal differentiation and catabolism)
(forward 5′-AATTTTCACTTTTGGCAATGA-3′; reverse 5′-CAAATAATTTATGAAAAAGGGATGC-3′),
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (housekeeping gene and internal control)
(forward 5′-GAAGGTGAAGGTCGGAGTC-3′; reverse 5′-GAAGATGGTGATGGGATTTC-3′) [13–17].
Control conditions included reactions using water and non-reverse-transcribed mRNA. The specificity
of the products was confirmed by melting curve analysis and agarose gel electrophoresis. The threshold
cycle (Ct) value for each gene of interest was measured for each amplified sample using MxPro
QPCR software (Stratagene), and values were normalized to GAPDH expression by using the 2−∆∆Ct
method [13–17].
2.11. Statistical Analysis
Each condition was performed in duplicate in three independent experiments for each patient.
All hMSCs aggregates were tested for all experiments using the human OCDs. Results are expressed as the
mean ± standard deviation (SD). A t-test was employed with p < 0.05 considered statistically significant.
3. Results
3.1. Effective rAAV-Mediated Co-Overexpression of TGF-β and IGF-I in Human Osteochondral Defects Upon
Implantation of Genetically Modified hMSC Aggregates
The rAAV vectors were first applied to hMSC aggregates (n = 3) and (co-)transduced aggregates
were then directly implanted in human OCDs (n = 3) according to the study design (Figure 1) to test
the ability of rAAV to co-overexpress the therapeutic TGF-β and IGF-I candidates (TGF-β/IGF-I) over
time (21 days) versus independent gene transfer (TGF-β/lacZ or IGF-I/lacZ) and control (lacZ) condition
(endogenous growth factor expression). Effective expression of TGF-β and IGF-I via rAAV was noted
in the specific conditions examined, especially in the TGF-β/IGF-I OCDs (Table 1, Table 2 and Figure 2).
The levels of TGF-β production were higher in the TGF-β/IGF-I than in the lacZ, TGF-β/lacZ,
and IGF-I/lacZ OCDs (3.6-, 1.7-, and 3.5-fold difference, respectively, p ≤ 0.001) and in the TGF-β/lacZ
versus lacZ and IGF-I/lacZ OCDs (2.1-fold difference, p ≤ 0.010) while there was no difference between
the IGF-I/lacZ and lacZ OCDs (p = 0.500) (Table 1). The levels of IGF-I production were higher in
the TGF-β/IGF-I than in the lacZ, TGF-β/lacZ, and IGF-I/lacZ OCDs (1.4-, 1.3-, and 1.1-fold difference,
p = 0.010, p = 0.010, and p = 0.430, respectively) and in the IGF-I/lacZ versus lacZ and TGF-β/lacZ OCDs
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(1.3-fold difference, p ≤ 0.040) while there was no difference between the TGF-β/lacZ and lacZ OCDs
(p = 0.353) (Table 1).
Table 1. Transgene expression in human OCD supernatants following implantation of rAAV-transduced
hMSC aggregates (day 21). The levels of TGF-β production are in pg/mL and those of IGF-I in pg/mL.
Data are given as mean ± SD. Statistically significant relative to alacZ, bTGF-β/lacZ, and cIGF-I/lacZ;
TGF-β+, TGF-β-positive; IGF-I+, and IGF-positive.
Assay lacZ TGF-β/lacZ IGF-I/lacZ TGF-β/IGF-I
TGF-β+ 156 ± 74 333 ± 58 a,c 158 ± 90 556 ± 70 a,b,c
IGF-I+ 53 ± 7 55 ± 8 71 ± 16 a,b 73 ± 18 a,b
Table 2. Histomorphometric analyses in human osteochondral defects OCDs following implantation
of rAAV-transduced hMSC aggregates (day 21). TGF-β-positive (TGF-β+) and IGF-positive (IGF-I+)
cells are in %. The cell densities are as cells/mm2. Stained (safranin O) and immunostained (type-II, -I,
and -X collagen) sections were scored for uniformity and intensity according to modified Bern Score
grading system [19] as: 0 (no staining), 1 (heterogenous and/or weak staining), 2 (homogeneous and/or
moderate staining), 3 (homogeneous and/or intense staining) and 4 (very intense staining). Data are
given as mean ± SD. Statistically significant relative to alacZ, bTGF-β/lacZ, and cIGF-I/lacZ.
Assay lacZ TGF-β/lacZ IGF-I/lacZ TGF-β/IGF-I
TGF-β+ cells
OCD 12 ± 2 77 ± 8 a,c 12 ± 5 93 ± 1 a,b,c
surrounding cartilage 2 ± 1 62 ± 6 a,c 3 ± 1 74 ± 6 a,b,c
IGF-I+ cells
OCD 13 ± 3 18 ± 4 76 ± 3 a,b 86 ± 2 a,b,c
surrounding cartilage 6 ± 2 15 ± 4 56 ± 3 a,b 64 ± 5 a,b,c
Cell densities
OCD 3467 ± 115 5767 ± 1156 a 5608 ± 300 a 11,308 ± 1556 a,b,c
surrounding cartilage 145 ± 21 238 ± 75 a,c 168 ± 11 286 ± 80 a,b,c
Safranin O
OCD 0.3 ± 0.4 2.1 ± 0.8a,c 0.1 ± 0.4 2.4 ± 0.7 a,c
surrounding cartilage 1.3 ± 0.5 2.6 ± 1.0 a 1.9 ± 0.6 a 3.8 ± 0.5 a,b,c
Type-II collagen OCD 1.0 ± 0.8 3.0 ± 0.1
a,c 2.3 ± 0.5 a 3.8 ± 0.5 a,b,c
surrounding cartilage 0.5 ± 0.1 2.5 ± 0.6 a,c 1.8 ± 0.5 a 3.0 ± 0.8 a,c
Type-I collagen OCD 3.1 ± 0.8 1.5 ± 0.7
a,c 3.0 ± 0.5 1.1 ± 0.4 a,c
surrounding cartilage 2.9 ± 0.6 2.0 ± 0.8 a 2.6 ± 0.7 1.5 ± 0.5 a,c
Type-X collagen OCD 3.0 ± 0.8 1.9 ± 1.1
a 2.3 ± 0.9 1.3 ± 0.5 a
surrounding cartilage 2.9 ± 0.6 2.6 ± 0.5 2.1 ± 1.0 0.8 ± 0.7 a,b,c
Immunoreactivity to TGF-β was higher in the TGF-β/IGF-I than in the lacZ, TGF-β/lacZ, and
IGF-I/lacZ OCDs (7.8-, 1.2-, and 7.8-fold difference, respectively, p ≤ 0.020) and in the TGF-β/lacZ
versus lacZ and IGF-I/lacZ OCDs (6.4-fold difference, p ≤ 0.001) while there was no difference between
the IGF-I/lacZ and lacZ OCDs (p = 0.500) (Figure 2 and Table 2). In the surrounding cartilage,
TGF-β immunoreactivity was higher in the TGF-β/IGF-I than in the lacZ, TGF-β/lacZ, and IGF-I/lacZ
samples (37-, 1.2-, and 24.7-fold difference, respectively, p ≤ 0.040) and in the TGF-β/lacZ versus
lacZ and IGF-I/lacZ samples (31- and 20.7-fold difference, respectively, p = 0.005) while there was
no difference between the IGF-I/lacZ and lacZ samples (1.5-fold difference, p = 0.220) (Figure 2 and
Table 2). Immunoreactivity to IGF-I was higher in the TGF-β/IGF-I than in the lacZ, TGF-β/lacZ,
and IGF-I/lacZ OCDs (6.6-, 4.8-, and 1.2-fold difference, respectively, p ≤ 0.002) and in the IGF-I/lacZ
versus lacZ and TGF-β/lacZ OCDs (5.8 and 4.2-fold difference, respectively, p ≤ 0.001) while there
was no difference between the TGF-β/lacZ versus lacZ OCDs (p = 0.077) (Figure 2 and Table 2).
In the surrounding cartilage, IGF-I immunoreactivity was higher in the TGF-β/IGF-I than in the lacZ,
TGF-β/lacZ, and IGF-I/lacZ samples (10.7-, 4.3-, and 1.2-fold difference, respectively, p ≤ 0.041) and in
the IGF-I/lacZ versus lacZ and TGF-β/lacZ samples (9.3- and 3.7-fold difference, respectively, p ≤ 0.020)
while there was no difference between the TGF-β/lacZ versus lacZ samples (p = 0.240) (Figure 2 and
Table 2).
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described in Figure 1 and in the Materials and Methods. Samples were processed after 21 days to 
detect the expression of TGF-β and of IGF-I by immunohistochemistry (magnification ×10; insets 
showing the surrounding cartilage in the region immediately adjacent to the implanted pellets at 
magnification × 20; representative data). Scale bars: 100 µm, insets: 50 µm. 
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versus lacZ and TGF-β/lacZ samples (9.3- and 3.7-fold difference, respectively, p ≤ 0.020) while there 
was no difference between the TGF-β/lacZ versus lacZ samples (p = 0.240) (Figure 2 and Table 2). 
3.2. Biological and Chondrogenic Differentiation Activities in Human Osteochondral Defects Mediated by 
Co-Overexpression of TGF-β and IGF-I via rAAV in Implanted hMSC Aggregates 
The hMSC aggregates (n = 3) transduced with the various rAAV vectors were next directly 
implanted in human OCDs (n = 3) to determine the capacity of the TGF-β/IGF-I combination to 
Figure 2. Detection of transgene (TGF-β, IGF-I) overexpression in human OCDs following implantation
of rAAV-transduced hMSC aggregates. Aggregates were cotransduced with rAAV TGF-β/IGF-I,
TGF-β/lacZ, IGF-I/lacZ or transduced with rAAV lacZ and implanted in human OCDs as described
in Figure 1 and in the Materials and Methods. Samples were processed after 21 days to detect the
expression of TGF-β and of IGF-I by immunohistochemistry (magnification ×10; insets showing the
surrounding cartilage in the region immediately adjacent to the implanted pellets at magnification × 20;
representative data). Scale bars: 100 µm, insets: 50 µm.
3.2. Biological and Chondrogenic Differentiation Activities in Human Osteochondral Defects Mediated by
Co-Overexpression of TGF-β and IGF-I via rAAV in Implanted hMSC Aggregates
The hMSC aggregates (n = 3) transduced with the various rAAV vectors were next directly
implanted in human OCDs (n = 3) to determine the capacity of the TGF-β/IGF-I combination to enhance
the proliferative, anabolic, and chondrogenic activities in sites of transplantation in situ over time
(21 days) versus independent gene (TGF-β/lacZ or IGF-I/lacZ) and control (lacZ) gene treatments.
The DNA contents were higher in the TGF-β/IGF-I versus lacZ, TGF-β/lacZ, and IGF-I/lacZ OCDs
(1.3-, 1.2-, and 1.3-fold difference, respectively, p ≤ 0.020) and in the TGF-β/lacZ versus lacZ and
IGF-I/lacZ OCDs (1.2-fold difference, p ≥ 0.060) while there was no difference between the IGF-I/lacZ
and lacZ OCDs (p = 0.440) (Table 3).
Table 3. Biological activities in human OCDs following implantation of rAAV-transduced hMSC
aggregates (day 21). The DNA contents a in ng/µg total proteins, the pr teoglycan contents in
µg/mg total proteins, and the proteoglycan/DNA contents in µg/ng. Data are given as me n ± SD.
Statistically significant relative to alacZ, bTGF-β/lacZ, and cIGF-I/lacZ.
Assay lacZ TGF-β/lacZ IGF-I/lacZ TGF-β/IGF-I
DNA 0.39 ± 0.26 0.45 ± 0.30 0.39 ± 0.25 0.52 ± 0.32 a,b,c
Proteoglycans 12 ± 7 17 ± 12 a 15 ± 8 22 ± 13 a,b,c
Proteoglycans/DNA 0.11 ± 0.05 0.13 ± 0.07 a 0.12 ± 0.05 0.15 ± 0.07 a,b,c
The cell densities were higher in the TGF-β/IGF-I versus lacZ, TGF-β/lacZ, and IGF-I/lacZ OCDs
(3.2-, 2-, and 2-fold difference, respectively, p ≤ 0.020), in the TGF-β/lacZ versus lacZ OCDs (1.7-fold
difference, p = 0.044), and in the IGF-I/lacZ versus lacZ OCDs (1.6-fold difference, p = 0.006) while there
was no difference between the TGF-β/lacZ and IGF-I/lacZ OCDs (p = 0.390) (Figure 3 and Table 2).
In the cartilage surrounding the OCDs, the cell densities were higher in the TGF-β/IGF-I versus lacZ,
TGF-β/lacZ, and IGF-I/lacZ samples (2-, 1.2-, and 1.7-fold difference, respectively, p ≤ 0.040), in the
TGF-β/lacZ versus lacZ and IGF-I/lacZ samples (1.6- and 1.4-fold difference, respectively, p ≤ 0.040),
and in the IGF-I/lacZ and lacZ samples (1.2-fold difference, p = 0.090) (Figure 3 and Table 2).
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Figure 3. Biological, chondrogenic, osteogenic, and hypertrophic differentiation activities in human
OCDs following implantation of rAAV-transduced hMSC aggregates. Aggregates were cotransduced
with rAAV TGF-β/IGF-I, TGF-β/lacZ, IGF-I/lacZ or transduced with rAAV lacZ and implanted in human
OCDs as described in Figures 1 and 2 and in the Materials and Methods. Samples were processed after
21 days to evaluate cellularity (H&E staining) and the deposition of matrix proteoglycans (safranin
O staining), type-II/-I/-X collagen (immunohistochemistry) (for each type of staining: top panel at
magnification × 10 with scale bars of 500 µm, bottom panels including the region immediately adjacent
to the implanted pellets at magnification ×20 with scale bars of 200 µm; representative data).
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The anabolic and chondrogenic differentiation activities were higher in the TGF-β/IGF-I versus
lacZ, TGF-β/lacZ, and IGF-I/lacZ OCDs (proteoglycans: 1.8-, 1.3-, and 1.5-fold difference, respectively,
p ≤ 0.020; proteoglycans/DNA: 1.4-, 1.2-, and 1.3-fold difference, respectively, p ≤ 0.030; safranin O:
8-, 1.1-, and 24-fold difference, p ≤ 0.001, p = 0.260, and p ≤ 0.001, respectively; type-II collagen: 3.8-,
and 1.7-fold difference, respectively, p ≤ 0.030), in the TGF-β/lacZ versus lacZ and IGF-I/lacZ OCDs
(proteoglycans: 1.4- and 1.2-fold difference, p = 0.030 and p = 0.200, respectively; proteoglycans/DNA:
1.2- and 1.1-fold difference, respectively, p = 0.030 and p = 0.150; safranin O: 7- and 21-fold difference,
respectively, p ≤ 0.001; type-II collagen: 3- and 1.3-fold difference, respectively, p ≤ 0.030), and in the
IGF-I/lacZ versus lacZ OCDs (proteoglycans: 1.3-fold difference, p = 0.090; proteoglycans/DNA: 1.1-fold
difference, p = 0.280; type-II collagen: 2.3-fold difference, p = 0.010) while there was no difference
between the IGF-I/lacZ and lacZ OCDs for safranin O staining (p = 0.500) (Table 2, Table 3 and Figure 3).
In the cartilage surrounding the OCDs, the chondrogenic differentiation activities were higher in
the TGF-β/IGF-I versus lacZ, TGF-β/lacZ, and IGF-I/lacZ samples (safranin O: 2.9-, 1.5-, and 2-fold
difference, respectively, p ≤ 0.030; type-II collagen: 6-, 1.2-, and 1.7-fold difference, p = 0.002, p = 0.100,
and p = 0.040, respectively), in the TGF-β/lacZ versus lacZ and IGF-I/lacZ samples (safranin O: 2- and
1.4-fold difference, p = 0.010 and p = 0.080, respectively; type-II collagen: 5- and 1.4-fold difference,
respectively, p ≤ 0.030), and in the IGF-I/lacZ versus lacZ samples (safranin O: 1.5-fold difference,
p ≤ 0.030; type-II collagen: 3.6-fold difference, p = 0.040) (Table 2, Table 3 and Figure 3).
3.3. Influence of Co-Overexpression of TGF-β and IGF-I via rAAV Upon the Osteogenic and Hypertrophic
Differentiation Activities in Human Osteochondral Defects Upon Implantation of Genetically Modified
hMSC Aggregates
The hMSC aggregates (n = 3) transduced with rAAV were then directly implanted in human
OCDs (n = 3) to determine the potential influence of the TGF-β/IGF-I combination on the osteogenic
and hypertrophic activities in transplanted sites in situ over time (21 days) versus independent gene
delivery (TGF-β/lacZ or IGF-I/lacZ) and control (lacZ) treatment.
The osteogenic differentiation activities (type-I collagen deposition) were lower in the TGF-β/IGF-I
versus lacZ, TGF-β/lacZ, and IGF-I/lacZ OCDs (2.8-, 1.4-, and 2.7-fold difference, p ≤ 0.001, p = 0.090,
and p ≤ 0.001, respectively) and in the TGF-β/lacZ versus lacZ and IGF-I/lacZ OCDs (2.1- and 2-fold
difference, respectively, p ≤ 0.001) while there was no difference between the IGF-I/lacZ and lacZ OCDs
(p = 0.400) (Figure 3 and Table 2). In the cartilage surrounding the OCDs, the osteogenic differentiation
activities were lower in the TGF-β/IGF-I versus lacZ, TGF-β/lacZ, and IGF-I/lacZ samples (1.9-, 1.3-,
and 1.7-fold difference, p ≤ 0.001, p = 0.120, and p ≤ 0.001, respectively), in the TGF-β/lacZ versus lacZ
and IGF-I/lacZ samples (1.5- and 1.3-fold difference, p = 0.020 and p = 0.130, respectively), and in the
IGF-I/lacZ and lacZ samples (1.1-fold difference, p = 0.230) (Figure 3 and Table 2).
The hypertrophic differentiation activities (type-X collagen deposition) were lower in the
TGF-β/IGF-I versus lacZ, TGF-β/lacZ, and IGF-I/lacZ OCDs (2.3-, 1.5-, and 1.8-fold difference, p ≤ 0.001,
p = 0.100, and p = 0.100, respectively), in the TGF-β/lacZ versus lacZ and IGF-I/lacZ OCDs (1.6- and
1.2-fold difference, respectively, p ≤ 0.001 and p = 0.260, respectively), and in the IGF-I/lacZ versus lacZ
OCDs (1.3-fold difference, p = 0.090) (Figure 3 and Table 2). In the cartilage surrounding the OCDs,
the hypertrophic differentiation activities were lower in the TGF-β/IGF-I versus lacZ, TGF-β/lacZ,
and IGF-I/lacZ samples (3.6-, 3.3-, and 2.6-fold difference, respectively, p ≤ 0.007), in the TGF-β/lacZ
versus lacZ samples (1.1-fold difference, p = 0.230), in the IGF-I/lacZ versus samples (1.4-fold difference,
p = 0.060), and and in the IGF-I/lacZ versus TGF-β/lacZ samples (1.2-fold difference, p = 0.230) (Figure 3
and Table 2).
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3.4. Real-Time RT-PCR Analyses in Human Osteochondral Defects Mediated by Co-Overexpression of TGF-β
with IGF-I via rAAV in Implanted hMSC Aggregates
These results were corroborated by real-time RT-PCR analysis in human OCDs (n = 3) where
rAAV-transduced (TGF-β/IGF-I versus TGF-β/lacZ, IGF-I/lacZ, and lacZ) hMSC aggregates (n = 3) were
implanted over time (21 days) (Figure 4).
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Figure 4. Real-time RT-PCR analyses in human OCDs following implantation of rAAV-transduced
hMSC aggregates. Aggregates were cotransduced with rAAV TGF-β/IGF-I, TGF-β/lacZ, IGF-I/lacZ or
transduced with rAAV lacZ and implanted in human OCDs as described in Figures 1–3 and in the
Materials and Methods. Samples were processed after 21 days to monitor the gene expression profiles
by real-time RT-PCR as described in the Materials and Methods. The genes analyzed included the
transcription factor SOX9, type-II collagen (COL2A1), aggrecan (ACAN), type-I collagen (COL1A1),
type-X collagen (COL10A1), and matrix metalloproteinase 13 (MMP13), with GAPDH serving as a
housekeeping gene and internal control. Threshold cycle (Ct) values were obtained for each target and
GAPDH as a control for normalization, and fold inductions (relative to OCDs where lacZ aggregates
were implanted) were measured using the 2−∆∆Ct method. Statistically significant relative to alacZ,
bTGF-β/lacZ, and cIGF-I/lacZ.
Enhanced chondrogenic differentiation was observed by higher SOX9 expression in the
TGF-β/IGF-I versus lacZ, TGF-β/lacZ, and IGF-I/lacZ OCDs (6.4-, 3.1-, and 3.7-fold difference, p ≤ 0.014),
in the TGF-β/lacZ versus lacZ and IGF-I/lacZ OCDs (2.1- and 1.7-fold difference, respectively, p ≤ 0.042),
and in the IGF-I/lacZ versus lacZ OCDs (1.7-fold difference, p≤ 0.001) (Figure 4). Enhanced chondrogenic
COL2A1 expression was also seen in the TGF-β/IGF-I versus lacZ, TGF-β/lacZ, and IGF-I/lacZ OCDs
(6.1-, 2.7-, and 5.3-fold difference, p = 0.057, p = 0.032, and p ≤ 0.001, respectively), in the TGF-β/lacZ
versus lacZ and IGF-I/lacZ OCDs (2.2- and 2-fold difference, respectively, p≥ 0.099), and in the IGF-I/lacZ
versus lacZ OCDs (1.1-fold difference, p = 0.118) (Figure 4). Higher chondrogenic ACAN expression was
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also evidenced in the TGF-β/IGF-I versus lacZ, TGF-β/lacZ, and IGF-I/lacZ OCDs (6.4-, 3-, and 4.1-fold
difference, p = 0.012, p = 0.066, and p = 0.054, respectively), in the TGF-β/lacZ versus lacZ and IGF-I/lacZ
OCDs (2.2- and 1.4-fold difference, p = 0.007 and p = 0.186, respectively), and in the IGF-I/lacZ versus
lacZ OCDs (1.6-fold difference, p = 0.083) (Figure 4).
Restricted osteogenic differentiation was seen by lower COL1A1 expression in the TGF-β/IGF-I
versus lacZ, TGF-β/lacZ, and IGF-I/lacZ OCDs (1.6-, 1.3-, and 1.5-fold difference, respectively, p ≤ 0.001),
in the TGF-β/lacZ versus lacZ and IGF-I/lacZ OCDs (1.2-fold difference, p ≤ 0.036), and in the IGF-I/lacZ
versus lacZ OCDs (1.1-fold difference, p = 0.002) (Figure 4).
Reduced hypertrophic differentiation was noted by lower COL10A1 expression in the TGF-β/IGF-I
versus lacZ, TGF-β/lacZ, and IGF-I/lacZ OCDs (1.4-, 1.3-, and 1.4-fold difference, p = 0.002, p = 0.069,
and p = 0.018, respectively) and in the TGF-β/lacZ versus IGF-I/lacZ and lacZ OCDs (1.1-fold difference,
p ≥ 0.181) while no difference was reported between the IGF-I/lacZ and lacZ OCDs (p = 0.440) (Figure 4).
Decreased catabolic processes were also observed by lower MMP13 expression in the TGF-β/IGF-I
versus lacZ, TGF-β/lacZ, and IGF-I/lacZ OCDs (16.7-, 1.4-, and 1.7-fold difference, p ≤ 0.005), in the
TGF-β/lacZ versus IGF-I/lacZ and lacZ OCDs (1.3- and 12.5-fold difference, p ≤ 0.001), and in the
IGF-I/lacZ and lacZ OCDs (10-fold difference, p ≤ 0.001) (Figure 4).
4. Discussion
Cell-based strategies using the application of progenitor cells to focal cartilage defects may be
of strong therapeutic value to enhance the intrinsic healing processes in sites of cartilage damage [7],
especially following modification of such cellular platforms by gene therapy procedures that aim at
stably triggering their chondroreparative activities [8,9]. Here, we tested the ability of the clinically
adapted rAAV gene transfer vectors to co-deliver the highly chondrogenic TGF-β and IGF-I growth
factors [11,15,16] to hMSCs for implantation in a model of human OCD that provides a natural
environment similar to that noted in patients in vivo [20,21] as a means to repopulate the defects upon
stimulation of the local healing processes relative to independent gene treatments and control (reporter
gene vector) condition.
The data first indicate that rAAV is capable of successfully promoting the concomitant, sustained
overexpression of TGF-β with IGF-I in hMSCs transplanted in human OCDs over the entire period
of evaluation (at least 21 days) relative to single and reporter gene treatments, in agreement with
the ability of rAAV to transduce and be maintained in such targets [11,13–16], especially in a
simultaneous fashion [17]. Of note, the amounts of each respective growth factor produced in the
OCDs were significantly higher upon the application of hMSCs co-transduced with TGF-β/IGF-I
relative to single, independent candidate gene treatments at similar vector doses, suggesting a possible
reciprocal regulation of growth factor expression as previously noted in articular chondrocytes [25].
The production levels of TGF-β and IGF-I raised from implanted TGF-β/lacZ- or IGF-I/lacZ-treated
hMSCs were comparable to those measured in our previous work using solely rAAV-hTGF-β or
rAAV-hIGF-I in hMSCs in vitro at equivalent MOIs (~ 70–300 pg/mL at MOI = 8) [15,16] or the
current combination in settings in vitro aiming at directly rejuvenating the cells (~ 50–100 pg/mL at
MOI = 8) [18]. Interestingly, transgene (co)-expression was also noted in the cartilage surrounding the
defects where the respective candidate treatments were applied, showing the potentially beneficial
production of the growth factors via rAAV-modified, transplanted cells at a distance. It remains to
be seen whether too high and/or prolonged levels of growth factor co-overexpression may have a
detrimental impact on tissue repair in this model system or in vivo—however, such an issue might be
addressed by applying various (lower) vector doses or using regulatable (tetracycline-controlled) or
tissue-specific promoters (sox9, type-II collagen) [26] instead of the strong CMV-IE regulatory element.
While no immune responses were expected in such a model ex vivo as it lacks the full spectrum of
immune components, they may occur in vivo [27] although to a low extent as rAAV has been reported
for its absence of deleterious effects when directly applied to focal defects in vivo [28].
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The results next show that significant, prolonged TGF-β/IGF-I co-overexpression from
co-transduced, implanted hMSCs triggered the biological and chondrodifferentiation activities in
human OCDs over time (cell proliferation, proteoglycan/type-II collagen deposition) more effectively
than when using each individual candidate gene treatment and versus control (lacZ) condition,
as a possible growth factor intercooperation [25] and concordant with the properties of TGF-β and
IGF-I [5,6,11,29] and with our work using the vectors independently [15,16] or simultaneously in a
direct transfer approach [18]. Such effects were also observed in the cartilage surrounding the defects,
likely due to the expression of the candidate transgenes at a distance and/or to the paracrine effects of
the factors secreted. A degree of variability was noted between samples, reflecting the different features
and background of the individual donors, but in good agreement with previous observations by Mackay
et al. [6] who reported similar discrepancies between human donors. Of note, as the gene expression
profiles were tested in bone-free OCD-implant systems due to the limited size of the cell-confined
aggregates, the contribution of the implants to such profiles remains to be determined [20] versus a
possible impact of the (slightly less active) chondrocytes in the surrounding cartilage. Despite such
results, integration between the implant and the host cartilage and self-repair (even for a small,
1-mm lesion) did not fully occur, in agreement with our previous observations using such a model
system [20], an outcome that might be achieved at much longer time points [30,31].
Finally, the data demonstrate the ability of combined rAAV-mediated TGF-β/IGF-I
co-overexpression in implanted hMSCs to prevent undesirable hypertrophic, terminal differentiation,
and osteogenic differentiation as well as catabolic processes over time in treated OCDs relative to
single candidate gene treatments and the control lacZ condition, probably due to higher levels
of SOX9 expression, a transcription factor known for its anti-hypertrophic and anti-catabolic
activities [14,32], and in agreement with our findings using a direct approach [18]. This is in
contrast with our previous findings when applying either rAAV-hTGF-β or rAAV-hIGF-I to hMSCs
in vitro [15,16] yet in these studies, a higher MOI was provided to the cells (MOI = 20 while we used
an MOI = 8 here, i.e., a 2.5-fold difference), showing that the optimal treatment will be a function of
the vector doses applied. Here also, these effects were seen in the cartilage surrounding the defects,
again probably resulting from the expression of the transgenes at a distance and/or to paracrine effects
of the products.
5. Conclusions
The present findings show the benefits of cell- and gene-based therapy using multiple therapeutic
rAAV gene transfer procedures in order to regenerate human articular cartilage lesions with an adapted
phenotype in a natural environment. Work is ongoing to evaluate the potential benefits of this indirect
regenerative approach in clinically relevant animal models of (orthotopic) cartilage defects in vivo
and to evaluate possible immune responses [33,34]. Overall, the current data provide a basis for the
future treatment of focal cartilage defects in human individuals using the patient’s self-reparative
progenitor cells.
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